Prediction of Response to Chemoradiation Therapy in Squamous Cell Carcinomas of the Head and Neck Using Dynamic Contrast-Enhanced MR Imaging

被引:161
作者
Kim, S. [1 ,2 ]
Loevner, L. A. [2 ]
Quon, H. [3 ]
Kilger, A. [2 ]
Sherman, E. [4 ]
Weinstein, G. [5 ]
Chalian, A. [5 ]
Poptani, H. [2 ]
机构
[1] NYU, Dept Radiol, Ctr Biomed Imaging, New York, NY 10016 USA
[2] Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA
[3] Univ Penn, Dept Radiat Oncol, Philadelphia, PA 19104 USA
[4] Univ Penn, Dept Hematol & Oncol, Philadelphia, PA 19104 USA
[5] Univ Penn, Dept Otolaryngol, Philadelphia, PA 19104 USA
基金
美国国家卫生研究院;
关键词
TRANSCYTOLEMMAL WATER-EXCHANGE; CR BOLUS-TRACKING; PHARMACOKINETIC ANALYSIS; TUMOR VASCULATURE; SHUTTER-SPEED; FOLLOW-UP; CANCER; RADIOTHERAPY; PERMEABILITY; CHEMOTHERAPY;
D O I
10.3174/ajnr.A1817
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
BACKGROUND AND PURPOSE: Tumor microenvironment, including blood flow and permeability, may provide crucial information regarding response to chemoradiation therapy. Thus, the objective of this study was to investigate the efficacy of pretreatment DCE-MR imaging for prediction of response to chemoradiation therapy in HNSCC. MATERIALS AND METHODS: DCE-MR imaging studies were performed on 33 patients with newly diagnosed HNSCC before neoadjuvant chemoradiation therapy by using a 1.5T (n = 24) or a 3T (n = 9) magnet. The data were analyzed by using SSM for estimation of K(trans), v(e), and tau(i). Response to treatment was determined on completion of chemoradiation as CR, with no evidence of disease (clinically or pathologically), or PR, with pathologically proved residual tumor. RESULTS: The average pretreatment K(trans) value of the CR group (0.64 +/- 0.11 minutes(-1), n= 24) was significantly higher (P=.001) than that of the PR (0.21 +/- 0.05 minutes(-1), n = 9) group. No significant difference was found in other pharmacokinetic model parameters: v(e) and tau(i), between the 2 groups. Although the PR group had larger metastatic nodal volume than the CR group, it was not significantly different (P=.276). CONCLUSIONS: These results indicate that pretreatment DCE-MR imaging can be potentially used for prediction of response to chemoradiation therapy of HNSCC.
引用
收藏
页码:262 / 268
页数:7
相关论文
共 50 条
  • [21] FDG-PET/contrast-enhanced CT as a post-treatment tool in head and neck squamous cell carcinoma: comparison with FDG-PET/non-contrast-enhanced CT and contrast-enhanced CT
    Suenaga, Yuko
    Kitajima, Kazuhiro
    Ishihara, Takeaki
    Sasaki, Ryohei
    Otsuki, Naoki
    Nibu, Ken-ichi
    Minamikawa, Tsutomu
    Kiyota, Naomi
    Sugimura, Kazuro
    EUROPEAN RADIOLOGY, 2016, 26 (04) : 1018 - 1030
  • [22] Dynamic Contrast-Enhanced MRI Evaluates the Early Response of Human Head and Neck Tumor Xenografts Following Anti-EMMPRIN Therapy With Cisplatin or Irradiation
    Kim, Hyunki
    Hartman, Yolanda E.
    Zhai, Guihua
    Chung, Thomas K.
    Korb, Melissa L.
    Beasley, Timothy M.
    Zhou, Tong
    Rosenthal, Eben L.
    JOURNAL OF MAGNETIC RESONANCE IMAGING, 2015, 42 (04) : 936 - 945
  • [23] Squamous cell carcinoma of the head and neck: diffusion-weighted MR imaging for prediction and monitoring of treatment response
    King, Ann D.
    Mo, Frankie K. F.
    Yu, Kwok-Hung
    Yeung, David K. W.
    Zhou, Hua
    Bhatia, Kunwar S.
    Tse, Gary M. K.
    Vlantis, Alexander C.
    Wong, Jeffrey K. T.
    Ahuja, Anil T.
    EUROPEAN RADIOLOGY, 2010, 20 (09) : 2213 - 2220
  • [24] Dynamic contrast-enhanced MRI and Doppler sonography in patients with squamous cell carcinoma of head and neck treated with induction chemotherapy
    Chawla, Sanjeev
    Loevner, Laurie
    Mohan, Suyash
    Lin, Alexander
    Sehgal, Chandra M.
    Poptani, Harish
    JOURNAL OF CLINICAL ULTRASOUND, 2022, 50 (09) : 1353 - 1359
  • [25] Translation of dynamic contrast-enhanced imaging onto a magnetic resonance-guided linear accelerator in patients with head and neck cancer
    Dubec, Michael J.
    Berks, Michael
    Price, James
    Mcdaid, Lisa
    Gaffney, John
    Little, Ross A.
    Cheung, Susan
    van Herk, Marcel
    Choudhury, Ananya
    Matthews, Julian C.
    Mcpartlin, Andrew
    Parker, Geoff J. M.
    Buckley, David L.
    O'Connor, James P. B.
    PHYSICS & IMAGING IN RADIATION ONCOLOGY, 2025, 33
  • [26] The assessment of irradiated bladder carcinoma using dynamic contrast-enhanced MR imaging
    Dobson, MJ
    Carrington, BM
    Collins, CD
    Ryder, WDJ
    Read, G
    Hutchinson, CE
    Hawnaur, JM
    CLINICAL RADIOLOGY, 2001, 56 (02) : 94 - 98
  • [27] Quantitative dynamic contrast-enhanced MR imaging analysis of complex adnexal masses: a preliminary study
    Thomassin-Naggara, Isabelle
    Balvay, Daniel
    Aubert, Emilie
    Darai, Emile
    Rouzier, Roman
    Cuenod, Charles A.
    Bazot, Marc
    EUROPEAN RADIOLOGY, 2012, 22 (04) : 738 - 745
  • [28] Dynamic Contrast-Enhanced MR Imaging Predicts Local Control in Oropharyngeal or Hypopharyngeal Squamous Cell Carcinoma Treated with Chemoradiotherapy
    Ng, Shu-Hang
    Lin, Chien-Yu
    Chan, Sheng-Chieh
    Yen, Tzu-Chen
    Liao, Chun-Ta
    Chang, Joseph Tung-Chieh
    Ko, Sheung-Fat
    Wang, Hung-Ming
    Huang, Shiang-Fu
    Lin, Yu-Chun
    Wang, Jiun-Jie
    PLOS ONE, 2013, 8 (08):
  • [29] Phase II trial of individualized/dynamic cisplatin regimens for definitive concurrent chemoradiation therapy in patients with head and neck squamous cell carcinoma
    Ahn, Dongbin
    Lee, Gil Joon
    Sohn, Jin Ho
    Lee, Jeong Eun
    CANCER MEDICINE, 2020, 9 (24): : 9256 - 9265
  • [30] Immunohistochemical and molecular imaging biomarker signature for the prediction of failure site after chemoradiation for head and neck squamous cell carcinoma
    Rasmussen, Gregers Brunnich
    Hakansson, Katrin E.
    Vogelius, Ivan R.
    Rasmussen, Jacob H.
    Friborg, Jeppe T.
    Fischer, Barbara M.
    Schumaker, Lisa
    Cullen, Kevin
    Therkildsen, Marianne H.
    Bentzen, Soren M.
    Specht, Lena
    ACTA ONCOLOGICA, 2017, 56 (11) : 1562 - 1570